- Home
- ACM vs BIIB Comparison
ACM vs BIIB Comparison
Compare ACM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACM | BIIB |
|---|---|---|
| Founded | 1980 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 24.2B |
| IPO Year | 2007 | 1991 |
Fundamental Metrics
Financial Performance| Metric | ACM | BIIB |
|---|---|---|
| Price | $103.00 | $181.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 23 |
| Target Price | $139.70 | ★ $176.48 |
| AVG Volume (30 Days) | 1.6M | ★ 1.9M |
| Earning Date | 11-18-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ 42.91 | N/A |
| EPS | 4.22 | ★ 10.97 |
| Revenue | ★ $16,139,622,000.00 | $10,065,900,000.00 |
| Revenue This Year | N/A | $3.61 |
| Revenue Next Year | $3.13 | N/A |
| P/E Ratio | $21.38 | ★ $16.52 |
| Revenue Growth | 0.21 | ★ 4.77 |
| 52 Week Low | $85.00 | $110.04 |
| 52 Week High | $135.52 | $185.17 |
Technical Indicators
Market Signals| Indicator | ACM | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 26.01 | 72.92 |
| Support Level | $101.07 | $174.53 |
| Resistance Level | $106.40 | $182.94 |
| Average True Range (ATR) | 4.37 | 5.22 |
| MACD | -0.82 | 0.25 |
| Stochastic Oscillator | 4.30 | 83.54 |
Price Performance
Historical ComparisonAbout ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).